Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10370767 | 0.87 | KDM4E (0.41) | KDM4ETDP1ALDH1A1HPGDGLA | |
| SCHEMBL1260300 | 0.84 | KDM4E (0.39) | KDM4ETDP1ALDH1A1HPGDGLA | |
| SCHEMBL3147406 | 0.84 | KDM4E (0.39) | KDM4ETDP1ALDH1A1HPGDGLA | |
| SCHEMBL11116972 | 0.84 | KDM4E (0.39) | KDM4ETDP1ALDH1A1HPGDGLA | |
| SCHEMBL28834516 | 0.84 | KDM4E (0.39) | KDM4ETDP1ALDH1A1HPGDGLA | |
| SCHEMBL7859850 | 0.82 | KEAP1 (0.46) | KDM4ETDP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL23804836 | 0.80 | CYP1A2 (0.51) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7022984 | 0.80 | SMN1; SMN2 (0.46) | KDM4ETDP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12474263 | 0.77 | LCK (0.44) | ALDH1A1HPGDGLAAKR1B1LMNA | |
| SCHEMBL9935525 | 0.76 | TDP1 (0.35) | KDM4ETDP1ALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939748-A | Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| CN-112939748-B | Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid | 中国科学院大连化学物理研究所 | 2022-11-01 | — | — | CN | disclosed |
| CN-112939748-A | Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | disclosed |
| US-20140309296-A1 | BUDIODARONE FORMULATIONS | ARMETHEON, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| CN-1205198-C | Cyclic ketone derivative and pharmaceutical use thereof | TORAY INDUSTRIES (JP) | 2005-06-08 | — | — | CN | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-0962456-A1 | CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5849788-A | Compound for treatment of cardiac arphythmia, synthesis, and methods of use | ARYX THERAPEUTICS (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0703910-B1 | BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA | ARYX THERAPEUTICS (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0703910-A1 | BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA | Advanced Therapies, Inc. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5440054-A | Compound for treatment of cardiac arrhythmia, synthesis, and methods of use | ADVANCED THERAPIES, INC. (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1994029289-A1 | BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA | ADVANCED THERAPIES, INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5364880-A | Compound for treatment of cardiac arrhythmia, synthesis, and methods of use | ADVANCED THERAPIES, INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0048954-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4460594-A | CENTRAL NERVOUS SYSTEM DISORDERS | BEECHAM GROUP P.L.C. (GB) | 1984-07-17 | — | — | US | disclosed |
| EP-0077607-A1 | N-substituted 3-aryl piperidines and derivatives thereof | BEECHAM GROUP PLC (GB) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309296-A1 | BUDIODARONE FORMULATIONS | ADH1A, ADH1C, CYP4B1 | KDM4E 2547/4885TDP1 2598/4885ALDH1A1 39/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | KDM4E 2751/4885TDP1 2952/4885ALDH1A1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.